8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Dec 4, 2025·SEC
Material company update
Oct 22, 2025·SEC
Palisade Bio, Inc.(PALI)Earnings, Financials & Key Ratios
PALI•NASDAQ
$2.00
$111M mkt cap·Price updated May 6, 2026
AboutPalisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.Show more
- Revenue$0
- EBITDA-$18M-21.5%
- Net Income-$17M-16.2%
- EPS (Diluted)-0.30+97.1%
- ROE-24.52%+84.0%
- Debt/Equity0.00-97.6%
- Interest Coverage-1805.60-45.8%
PALI Key Insights
Palisade Bio, Inc. (PALI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 87 (top 13%)
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PALI Price & Volume
Palisade Bio, Inc. (PALI) stock price & volume — 10-year historical chart
Loading chart...
PALI Growth Metrics
Palisade Bio, Inc. (PALI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-16.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM86.1%
Return on Capital
10 Years-889.29%
5 Years-423.58%
3 Years-96.58%
Last Year-26.29%
PALI Recent Earnings
Palisade Bio, Inc. (PALI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
Mar 23, 2026EPS
$0.04
Est $0.02
-100.0%
Revenue
—
Q4 2025
Nov 10, 2025EPS
$0.38
Est $0.32
-18.8%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$0.58
Est $0.48
-20.8%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.47
Est $0.84
+44.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 23, 2026 | $0.04vs $0.02-100.0% | — |
| Q4 2025 | Nov 10, 2025 | $0.38vs $0.32-18.8% | — |
| Q3 2025 | Aug 11, 2025 | $0.58vs $0.48-20.8% | — |
| Q2 2025 | May 12, 2025 | $0.47vs $0.84+44.0% | — |
Based on last 12 quarters of dataView full earnings history →
PALI Peer Comparison
Palisade Bio, Inc. (PALI) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 CHRS | 212.02M | 1.75 | 1.22 | -84.2% | 398.43% | 7.89% | 0.02 | |
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 VNDA | 439.76M | 7.44 | -1.99 | 8.72% | -102.02% | -49.24% | 0.04 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 |
Compare PALI vs Peers
Palisade Bio, Inc. (PALI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PALI Income Statement
Palisade Bio, Inc. (PALI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 260K | 260K | 15.39K | 0 | 0 | 0 | 250K | 0 | 0 |
| Revenue Growth % | 1500.39% | 0% | -94.08% | -100% | - | - | - | -100% | - |
| Cost of Goods Sold | 0 | -990K | 0 | 146K | 0 | 0 | 0 | 0 | 3K |
| COGS % of Revenue | - | -380.77% | - | - | - | - | - | - | - |
| Gross Profit | 260K▲ 0% | 1.25M▲ 380.8% | 15.39K▼ 98.8% | -146K▼ 1048.4% | 0▲ 100.0% | 0▲ 0% | 250K▲ 0% | 0▼ 100.0% | -3K▲ 0% |
| Gross Margin % | 100% | 480.77% | 100% | - | - | - | 100% | - | - |
| Gross Profit Growth % | 1500.39% | 380.77% | -98.77% | -1048.42% | 100% | - | - | -100% | - |
| Operating Expenses | 13.57M | 8.52M | 8.65M | 9.15M | 41.85M | 15.72M | 13.32M | 14.86M | 18.06M |
| OpEx % of Revenue | 5218.08% | 3276.54% | 56171.24% | - | - | - | 5328% | - | - |
| Selling, General & Admin | 5.18M | 4.37M | 4.44M | 6.05M | 9.31M | 8.76M | 6.2M | 5.8M | 7.86M |
| SG&A % of Revenue | 1993.08% | 1681.92% | 28855.4% | - | - | - | 2480.8% | - | - |
| Research & Development | 8M | 3.96M | 4.06M | 3.1M | 2.43M | 6.55M | 6.89M | 9.06M | 10.19M |
| R&D % of Revenue | 3078.46% | 1523.08% | 26380.41% | - | - | - | 2757.2% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 30.12M | 410K | 225K | 0 | 0 |
| Operating Income | -13.21M▲ 0% | -8.26M▲ 37.5% | -8.63M▼ 4.5% | -9.3M▼ 7.7% | -41.85M▼ 350.2% | -15.72M▲ 62.4% | -13.07M▲ 16.9% | -14.86M▼ 13.7% | -18.06M▼ 21.5% |
| Operating Margin % | -5082.69% | -3176.54% | -56073.79% | - | - | - | -5228% | - | - |
| Operating Income Growth % | 34.47% | 37.5% | -4.52% | -7.7% | -350.19% | 62.44% | 16.86% | -13.69% | -21.52% |
| EBITDA | -12.93M | -8.07M | -8.49M | -9.15M | -41.85M | -15.72M | -13.07M | -14.86M | -18.05M |
| EBITDA Margin % | -4971.46% | -3105.08% | -55139.28% | - | - | - | -5226.4% | - | - |
| EBITDA Growth % | 34.82% | 37.54% | -5.14% | -7.81% | -357.35% | 62.44% | 16.87% | -13.7% | -21.52% |
| D&A (Non-Cash Add-back) | 289.21K | 185.8K | 143.86K | 146K | 2K | 3K | 4K | 3K | 3K |
| EBIT | -15.51M | -4.92M | -8.34M | -10.09M | -24.22M | -14.25M | -12.29M | -14.43M | -18.06M |
| Net Interest Income | -88.8K | 71.08K | 58.81K | -235K | -2.4M | 0 | -15K | -12K | -10K |
| Interest Income | 70.27K | 78.78K | 67.73K | 0 | 0 | 13K | 0 | 0 | 0 |
| Interest Expense | 159.07K | 7.7K | 8.92K | 235K | 2.4M | 13K | 15K | 12K | 10K |
| Other Income/Expense | -2.45M | 3.33M | 280.04K | -1.02M | 15.24M | 1.46M | 770K | 421K | 1.27M |
| Pretax Income | -15.67M▲ 0% | -4.92M▲ 68.6% | -8.35M▼ 69.6% | -10.32M▼ 23.6% | -26.62M▼ 157.9% | -14.26M▲ 46.4% | -12.3M▲ 13.7% | -14.44M▼ 17.4% | -16.78M▼ 16.2% |
| Pretax Margin % | -6025.38% | -1894.23% | -54254.9% | - | - | - | -4920% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -15.67M▲ 0% | -4.92M▲ 68.6% | -8.35M▼ 69.6% | -10.32M▼ 23.6% | -26.62M▼ 157.9% | -14.26M▲ 46.4% | -12.3M▲ 13.7% | -14.44M▼ 17.4% | -16.78M▼ 16.2% |
| Net Margin % | -6025.38% | -1894.23% | -54254.9% | - | - | - | -4920% | - | - |
| Net Income Growth % | 25.67% | 68.56% | -69.58% | -23.59% | -157.86% | 46.42% | 13.74% | -17.38% | -16.23% |
| Net Income (Continuing) | -15.67M | -4.92M | -8.35M | -10.32M | -26.62M | -14.26M | -12.3M | -14.44M | -16.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -71.34▲ 0% | -18.02▲ 74.7% | -35.18▼ 95.2% | -186.00▼ 428.7% | -2546.10▼ 1268.9% | -16.53▲ 99.4% | -27.01▼ 63.4% | -10.19▲ 62.3% | -0.30▲ 97.1% |
| EPS Growth % | 43.43% | 74.74% | -95.23% | -428.71% | -1268.87% | 99.35% | -63.4% | 62.27% | 97.06% |
| EPS (Basic) | -71.59 | -18.02 | -14.78 | -186.00 | -2144.25 | -16.53 | -27.01 | -10.19 | -0.30 |
| Diluted Shares Outstanding | 219.6K | 273.24K | 237.39K | 237.39K | 12.46K | 880.3K | 456.01K | 1.42M | 55.67M |
| Basic Shares Outstanding | 218.84K | 273.24K | 122.41K | 832.3K | 12.41K | 880.1K | 456.01K | 1.42M | 55.67M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PALI Balance Sheet
Palisade Bio, Inc. (PALI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 12.45M | 6.51M | 5.65M | 896K | 11.51M | 14.73M | 13.33M | 10.49M | 134.22M |
| Cash & Short-Term Investments | 11.67M | 5.79M | 5.11M | 729K | 10.49M | 12.38M | 12.43M | 9.82M | 133.38M |
| Cash Only | 6.67M | 5.79M | 5.11M | 713K | 10.49M | 12.38M | 12.43M | 9.82M | 133.38M |
| Short-Term Investments | 5M | 0 | 0 | 16K | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 371.59K | 358K | 21.06K | 0 | 150K | 1.44M | 148K | 24K | 264K |
| Days Sales Outstanding | 521.65 | 502.57 | 499.44 | - | - | - | 216.08 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 100K | 0 | 114K | 112K | 87K | 572K |
| Total Non-Current Assets | 1.44M | 1.18M | 937.01K | 2.12M | 1.01M | 1.03M | 724K | 386K | 123K |
| Property, Plant & Equipment | 172.89K | 90.31K | 242.74K | 280K | 112K | 310K | 208K | 87K | 0 |
| Fixed Asset Turnover | 1.50x | 2.88x | 0.06x | - | - | - | 1.20x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 883.46K | 763.54K | 668.94K | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 365.46K | 298.24K | 0 | 0 | 0 | 26K | 0 | 26K | 55K |
| Other Non-Current Assets | 13.85K | 23.96K | 25.34K | 1.84M | 894K | 694K | 516K | 273K | 68K |
| Total Assets | 13.88M▲ 0% | 7.68M▼ 44.7% | 6.58M▼ 14.3% | 3.02M▼ 54.1% | 12.51M▲ 314.4% | 15.76M▲ 26.0% | 14.05M▼ 10.9% | 10.88M▼ 22.6% | 134.34M▲ 1134.8% |
| Asset Turnover | 0.02x | 0.03x | 0.00x | - | - | - | 0.02x | - | - |
| Asset Growth % | -38.58% | -44.65% | -14.32% | -54.15% | 314.44% | 25.98% | -10.85% | -22.57% | 1134.78% |
| Total Current Liabilities | 1.51M | 1.05M | 1.22M | 8.08M | 2.5M | 3.01M | 2.59M | 3.24M | 4.64M |
| Accounts Payable | 875.07K | 832.56K | 824.41K | 2.54M | 1.52M | 1.76M | 698K | 1.1M | 767K |
| Days Payables Outstanding | - | -306.96 | - | 6.34K | - | - | - | - | 93.32K |
| Short-Term Debt | 0 | 0 | 0 | 1.05M | 87K | 88K | 158K | 79K | 71K |
| Deferred Revenue (Current) | 0 | -4.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 220.88K | -756.4K | 124.67K | 0 | 511K | 574K | 831K | 0 | 3.8M |
| Current Ratio | 8.22x | 6.19x | 4.61x | 0.11x | 4.61x | 4.89x | 5.15x | 3.24x | 28.95x |
| Quick Ratio | 8.22x | 6.19x | 4.61x | 0.11x | 4.61x | 4.89x | 5.15x | 3.24x | 28.95x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 3.85M | 583.73K | 233.14K | 2.04M | 2.65M | 272K | 153K | 152K | 328K |
| Long-Term Debt | 0 | 535K | 0 | 94K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 148.54K | 112K | 0 | 211K | 90K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.85M | 48.73K | 84.59K | 1.83M | 2.65M | 61K | 63K | 152K | 328K |
| Total Liabilities | 5.37M | 1.63M | 1.46M | 10.12M | 5.15M | 3.28M | 2.74M | 3.39M | 4.96M |
| Total Debt | 0 | 5.04M | 288.54K | 1.42M | 199K | 404K | 369K | 169K | 71K |
| Net Debt | -6.67M | -749.11K | -4.83M | 708K | -10.3M | -11.98M | -12.06M | -9.65M | -133.31M |
| Debt / Equity | - | 0.83x | 0.06x | - | 0.03x | 0.03x | 0.03x | 0.02x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -83.08x | -1072.88x | -967.71x | -39.56x | -17.45x | -1209.31x | -871.33x | -1238.25x | -1805.60x |
| Total Equity | 8.52M▲ 0% | 6.05M▼ 29.0% | 5.13M▼ 15.3% | -7.1M▼ 238.5% | 7.37M▲ 203.7% | 12.48M▲ 69.4% | 11.31M▼ 9.3% | 7.49M▼ 33.8% | 129.38M▲ 1626.9% |
| Equity Growth % | -24.85% | -28.96% | -15.27% | -238.49% | 203.75% | 69.44% | -9.34% | -33.78% | 1626.91% |
| Book Value per Share | 38.78 | 22.14 | 21.59 | -29.90 | 590.95 | 14.18 | 24.81 | 5.29 | 2.32 |
| Total Shareholders' Equity | 8.52M | 6.05M | 5.13M | -7.1M | 7.37M | 12.48M | 11.31M | 7.49M | 129.38M |
| Common Stock | 151.6K | 182.05K | 38.66K | 28K | 3K | 30K | 93K | 27K | 1.59M |
| Retained Earnings | -208.7M | -213.62M | -221.98M | -68.03M | -94.64M | -109.19M | -121.51M | -135.94M | -152.72M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.63K | -413 | -6.19K | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PALI Cash Flow Statement
Palisade Bio, Inc. (PALI) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -13.42M | -7.69M | -7.26M | -4.77M | -14.77M | -13.36M | -11.13M | -12.19M | -10.85M |
| Operating CF Margin % | -5160.06% | -2958.62% | -47133.17% | - | - | - | -4453.2% | - | - |
| Operating CF Growth % | 14.09% | 42.66% | 5.68% | 34.29% | -209.84% | 9.56% | 16.67% | -9.52% | 11.04% |
| Net Income | -15.67M | -4.92M | -8.35M | -10.32M | -26.62M | -14.26M | -12.3M | -14.44M | -16.78M |
| Depreciation & Amortization | 289.21K | 185.8K | 143.86K | 3K | 2K | 3K | 4K | 3K | 3K |
| Stock-Based Compensation | 1.77M | 1.09M | 0 | 2.01M | 1.89M | 1.03M | 624K | 652K | 3.96M |
| Deferred Taxes | 0 | 0 | 0 | -38K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 6.47M | -2.29M | 743.83K | 1.19M | 14.71M | -1.39M | 139K | 199K | 337K |
| Working Capital Changes | -2.15M | -336.88K | 208.28K | 2.39M | -4.76M | 1.25M | 400K | 1.39M | 1.64M |
| Change in Receivables | -249.23K | 80.81K | 272.99K | -59K | 84K | 0 | 0 | 0 | 0 |
| Change in Inventory | -11.75M | 36.99K | 0 | -947K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.52M | -36.99K | -15.74K | 1.01M | 0 | 399K | -492K | 818K | 624K |
| Cash from Investing | -94.05K | 5M | 0 | -6K | -54K | -10K | -4K | 0 | 0 |
| Capital Expenditures | -94.05K | -1.71K | 0 | -6K | 0 | -10K | -4K | 0 | 0 |
| CapEx % of Revenue | 36.17% | 0.66% | - | - | - | - | 1.6% | - | - |
| Acquisitions | 82.64K | 0 | 0 | 0 | -54K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -82.64K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.99M | 1.81M | 6.59M | 1.89M | 24.61M | 15.26M | 11.19M | 9.58M | 134.44M |
| Debt Issued (Net) | -3.75M | -13.77K | 36.43K | 802K | -183K | -790K | -391K | -426K | -320K |
| Equity Issued (Net) | 8.74M | 1.83M | 6.55M | 1.18M | 25.11M | 14.4M | 9.42M | 8.44M | 135.25M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | -87K | -317K | 1.65M | 2.16M | 1.57M | -495K |
| Net Change in Cash | -8.52M▲ 0% | -887.83K▲ 89.6% | -672.19K▲ 24.3% | -2.88M▼ 329.0% | 9.78M▲ 439.2% | 1.89M▼ 80.7% | 49K▼ 97.4% | -2.61M▼ 5428.6% | 123.59M▲ 4833.6% |
| Free Cash Flow | -13.51M▲ 0% | -7.69M▲ 43.0% | -7.26M▲ 5.7% | -4.77M▲ 34.2% | -14.77M▼ 209.4% | -13.37M▲ 9.5% | -11.14M▲ 16.7% | -12.19M▼ 9.5% | -10.85M▲ 11.0% |
| FCF Margin % | -5196.23% | -2959.28% | -47133.17% | - | - | - | -4454.8% | - | - |
| FCF Growth % | 14.37% | 43.05% | 5.7% | 34.2% | -209.45% | 9.5% | 16.7% | -9.48% | 11.04% |
| FCF per Share | -61.52 | -28.16 | -30.56 | -20.11 | -1185.35 | -15.19 | -24.42 | -8.61 | -0.19 |
| FCF Conversion (FCF/Net Income) | 0.86x | 1.56x | 0.87x | 0.46x | 0.56x | 0.94x | 0.91x | 0.84x | 0.65x |
| Interest Paid | 0 | 0 | 0 | 0 | 64K | 0 | 0 | 14K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PALI Key Ratios
Palisade Bio, Inc. (PALI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -258.62% | -157.88% | -67.63% | -149.47% | - | -20012.03% | -143.72% | -103.4% | -153.55% | -24.52% |
| Return on Invested Capital (ROIC) | -377.18% | -1178.64% | -173.49% | -231.21% | - | - | - | - | - | - |
| Gross Margin | 100% | 100% | 480.77% | 100% | - | - | - | 100% | - | - |
| Net Margin | -129724.24% | -6025.38% | -1894.23% | -54254.9% | - | - | - | -4920% | - | - |
| Debt / Equity | 0.33x | - | 0.83x | 0.06x | - | 0.03x | 0.03x | 0.03x | 0.02x | 0.00x |
| Interest Coverage | -17.67x | -83.08x | -1072.88x | -967.71x | -39.56x | -17.45x | -1209.31x | -871.33x | -1238.25x | -1805.60x |
| FCF Conversion | 0.74x | 0.86x | 1.56x | 0.87x | 0.46x | 0.56x | 0.94x | 0.91x | 0.84x | 0.65x |
| Revenue Growth | 55.96% | 1500.39% | 0% | -94.08% | -100% | - | - | - | -100% | - |
PALI SEC Filings & Documents
Palisade Bio, Inc. (PALI) SEC filings — annual & quarterly reports (10-K, 10-Q)
PALI Frequently Asked Questions
Palisade Bio, Inc. (PALI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Palisade Bio, Inc. (PALI) grew revenue by 0.0% over the past year. Growth has been modest.
Palisade Bio, Inc. (PALI) reported a net loss of $16.8M for fiscal year 2025.
Dividend & Returns
Palisade Bio, Inc. (PALI) has a return on equity (ROE) of -24.5%. Negative ROE indicates the company is unprofitable.
Palisade Bio, Inc. (PALI) had negative free cash flow of $10.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More PALI
Palisade Bio, Inc. (PALI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates